Spero's Scientific Exchange

Posters and Publications

Filter all Publications & Posters

Download a complete bibliography from each of our ongoing investigational programs below.

Filters
Tebipenem HBr
SPR720
SPR206
SPR741

Tebipenem HBR

PK/PD

Pharmacokinetics and pharmacodynamics of SPR994 for multidrug resistant Enterobacteriaceae

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multidrug resistant Enterobacteriaceae in a hollow fibre infection model 

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with varying degrees of renal impairment

2021
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Pharmacodynamics of ertapenem

2019
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil is non-inferior to IV ertapenem in complicated urinary tract infection and acute pyelonephritis: ADAPT-PO Study

2022
SHM
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02469-20.

2021
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 2022;386:1327-38.

2022
Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical
Microbiology

Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro infection model

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Molecular epidemiology of Escherichia coli causing urinary tract infections in United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018–2020)

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR206

Reviews

SPR206: Next generation polymyxin for the treatment of highly resistant gram-negative bacterial infections

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR206

Non-Clinical
Reviews

Optimization of next-generation polymyxins leading to SPR206 as a development candidate

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Monitoring the in vitro activity of tebipenem, an orally available carbapenem agent, against a current collection of surveillance Enterobacteriaceae clinical isolates (2018)

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Medicare spending on urinary tract infections: a retrospective database analysis

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR741

No items found.

Mendes RE, Rhomberg PR, Lister T, et al. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Microb Drug Resist. 2020 Apr;26(4):319-328.

2020
Microbiology
ARCHIVE
View Full Text Link
Open Resource

SPR741

No items found.

Mendes RE, Rhomberg PR, Lister T, et al. In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae, Including Molecularly Characterized Strains. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00742-20.

2020
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

McEntee L, Johnson A, Farrington N, et al. Pharmacodynamics of tebipenem: New options for oral treatment of multidrug-resistant gram-negative infections. Antimicrob Agents Chemother. 2019 Jul 25;63(8): e00603-19. 

2019
PK/PD
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology
Reviews

Mechanism of action of SPR206, a next-generation polymyxin active against gram-negative pathogens

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Lodise TP, Chopra T, Nathanson BH, Sulham K. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021 May 30:S0196-6553(21)00382-5.

2021
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522.

2018
Reviews
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Lacasse E, Brouillette E, Larose A, et al. In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.

2019
Microbiology
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01503-18.

2019
Microbiology
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

Brown P, Abdulle O, Boakes S, et al. Influence of  Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin. ACS Infect Dis. 2021 Apr 9;7(4):894-905.

2021
Non-Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology
Non-Clinical

In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Non-Clinical

In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology
Non-Clinical

In vivo efficacy of SPR206 in murine lung and thigh infection models caused by multi-drug resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology
Non-Clinical

In vivo efficacy of SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro minimum inhibitory and minimum bactericidal concentrations of tebipenem and comparators against contemporary Enterobacterales tested in pooled human urine at varied pH

2021
World Microbe Forum
ARCHIVE
View Full Text Link
Open Resource

SPR206

Non-Clinical

In vivo efficacy of next-generation polymyxin SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology

In vitro characterization of a novel gyrase inhibitor (SPR719) against nontuberculous Mycobacteria

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Non-Clinical
Microbiology

In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract model

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

In vitro bactericidal activity of next-generation polymyxin SPR206 against susceptible and multidrug-resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae as compared to levofloxacin and meropenem

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM)

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem (SPR859), tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative bacteria

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance gram-positive clinical isolates

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology

In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital costs and reimbursement in patients with resistant Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology

In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera - pipeline drugs to treat

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

In vitro activity evaluation of a next-generation polymyxin, SPR206, against non-fermentative gram-negative bacilli responsible for human infections

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

SPR741

Microbiology

In vitro activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria

2018
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Impact of varied test conditions on the in vitro activity of tebipenem (SPR859) and meropenem against urinary pathogens, including those expressing extended-spectrum beta-lactamases (ESBL)

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource
No results found.
There are no results with this criteria. Try changing your search.

Unable to find what you were looking for?  

Download a complete bibliography from each of our ongoing investigational programs below.

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.